{"component": "definition", "props": {"groups": [{"size": 4, "snippet_links": [{"key": "the-collaboration", "type": "clause", "offset": [139, 156]}], "samples": [{"hash": "gAarjidelxw", "uri": "/contracts/gAarjidelxw#collaboration-field", "label": "Collaboration Agreement (pSivida LTD)", "score": 21.0, "published": true}, {"hash": "4VRshGaB2R5", "uri": "/contracts/4VRshGaB2R5#collaboration-field", "label": "Collaboration Agreement (Alimera Sciences Inc)", "score": 21.0, "published": true}, {"hash": "dyi8fPOi5w6", "uri": "/contracts/dyi8fPOi5w6#collaboration-field", "label": "Collaboration Agreement (pSivida LTD)", "score": 18.0, "published": true}], "snippet": "means the treatment and prevention of eye diseases in humans; provided, however, that the treatment and prevention of [*] is excluded from the Collaboration Field.", "hash": "ddb2d41c4a4fc0ff70b277467623125f", "id": 1}, {"size": 4, "snippet_links": [{"key": "the-collaboration", "type": "clause", "offset": [143, 160]}], "samples": [{"hash": "7uS2iH1VzaB", "uri": "/contracts/7uS2iH1VzaB#collaboration-field", "label": "Collaboration Agreement (pSivida Corp.)", "score": 21.3148528405, "published": true}, {"hash": "6RobNxWYQLo", "uri": "http://investors.psivida.com/static-files/5c94908e-a134-4dfc-bb65-091238a8834d", "label": "investors.psivida.com", "score": 9.205338809, "published": false}], "snippet": "means the treatment and prevention of eye diseases in humans; provided, however, that the treatment and prevention of uveitis is excluded from the Collaboration Field.", "hash": "1eff94c0215cf992f3d097d0df761b1d", "id": 2}, {"size": 3, "snippet_links": [{"key": "field-of", "type": "definition", "offset": [10, 18]}, {"key": "zip-code", "type": "definition", "offset": [19, 27]}, {"key": "in-combination", "type": "definition", "offset": [43, 57]}], "samples": [{"hash": "ejAemTKAE0b", "uri": "/contracts/ejAemTKAE0b#collaboration-field", "label": "Joint Development Agreement (Illumina Inc)", "score": 18.0, "published": true}, {"hash": "8bwjwPdySni", "uri": "/contracts/8bwjwPdySni#collaboration-field", "label": "Joint Development Agreement (Illumina Inc)", "score": 18.0, "published": true}, {"hash": "6rQHcbyB5WG", "uri": "/contracts/6rQHcbyB5WG#collaboration-field", "label": "Joint Development Agreement (Illumina Inc)", "score": 18.0, "published": true}], "snippet": "means the field of Zip Code Chemistry used in combination with Assembled Arrays.", "hash": "deda9d8250094a260c6de0343392317a", "id": 3}, {"size": 2, "snippet_links": [], "samples": [{"hash": "6mbmHp09FMZ", "uri": "/contracts/6mbmHp09FMZ#collaboration-field", "label": "Research and Development Collaboration Agreement (NextCure, Inc.)", "score": 30.2758384668, "published": true}, {"hash": "avpmikwIzWh", "uri": "/contracts/avpmikwIzWh#collaboration-field", "label": "Research and Development Collaboration Agreement (NextCure, Inc.)", "score": 30.0787132101, "published": true}], "snippet": "means all oncology applications and oncology uses.", "hash": "a50d9e74bd9b090c28f56ffab9e29a88", "id": 4}, {"size": 2, "snippet_links": [{"key": "treatment-of", "type": "definition", "offset": [37, 49]}, {"key": "not-limited", "type": "clause", "offset": [73, 84]}, {"key": "companion-diagnostics", "type": "definition", "offset": [187, 208]}], "samples": [{"hash": "jld1bpzWwys", "uri": "/contracts/jld1bpzWwys#collaboration-field", "label": "Joint Development and Option Agreement (Anixa Biosciences Inc)", "score": 35.4229979466, "published": true}, {"hash": "eoTYF0YXxPn", "uri": "https://ir.anixa.com/sec-filings/content/0001493152-24-022573/0001493152-24-022573.pdf", "label": "ir.anixa.com", "score": 10.2114989733, "published": false}], "snippet": "means vaccines for the prevention or treatment of cancers, including but not limited to breast, ovary, prostate, lung, colon and other cancers, as well as corresponding adjuvants and any companion diagnostics.", "hash": "5021a8e97086ca52ec6be264a55c94ec", "id": 5}, {"size": 2, "snippet_links": [{"key": "the-scope-of-services", "type": "clause", "offset": [6, 27]}, {"key": "related-to", "type": "clause", "offset": [28, 38]}, {"key": "design-works", "type": "definition", "offset": [54, 66]}, {"key": "for-development", "type": "clause", "offset": [67, 82]}], "samples": [{"hash": "cjoJjJlWyy5", "uri": "/contracts/cjoJjJlWyy5#collaboration-field", "label": "CSP Technology Collaboration Agreement (Vast Renewables LTD)", "score": 32.8069815195, "published": true}, {"hash": "1dSyFcqrawV", "uri": "https://www.sec.gov/Archives/edgar/data/1964630/000110465923117052/tm2310710d18_ex10-17.htm", "label": "Vast Renewables LTD", "score": 17.864476386, "published": false}], "snippet": "means the scope of services related to conceptual and design works for development, evaluation and advancing of heliostat designs and technology;", "hash": "1ccbad53dc8a301a833aa4fae51fd724", "id": 6}, {"size": 2, "snippet_links": [{"key": "the-collaboration", "type": "clause", "offset": [17, 34]}, {"key": "designated-antigen", "type": "definition", "offset": [96, 114]}], "samples": [{"hash": "ii2E6pPqyM2", "uri": "/contracts/ii2E6pPqyM2#collaboration-field", "label": "Collaboration Agreement (Seattle Genetics Inc /Wa)", "score": 21.0, "published": true}, {"hash": "fmgRkxXTGq9", "uri": "/contracts/fmgRkxXTGq9#collaboration-field", "label": "Collaboration Agreement (Seattle Genetics Inc /Wa)", "score": 21.0, "published": true}], "snippet": "means the [***]. The Collaboration Field does not include [***] whether or not Derived from any Designated Antigen.", "hash": "944a3a44f3cccfa67fbb245bf11edf0e", "id": 7}, {"size": 2, "snippet_links": [{"key": "the-collaboration", "type": "clause", "offset": [317, 334]}, {"key": "excluded-field", "type": "definition", "offset": [362, 376]}], "samples": [{"hash": "4NV5rXdFPBd", "uri": "/contracts/4NV5rXdFPBd#collaboration-field", "label": "Collaboration Agreement (Amgen Inc)", "score": 21.0, "published": true}], "snippet": "means the use of Ivory in any Collaboration SKU (including 60mg Collaboration SKU presentations) for the treatment, palliation or prevention of one (1) or more of the following diseases and conditions in humans: (i) post-menopausal osteoporosis; (ii) glucocorticoid induced osteoporosis; and (iii) male osteoporosis. The Collaboration Field does not include the Excluded Field.", "hash": "e32af6ec77355a07dea1e11fa6e2320d", "id": 8}, {"size": 1, "snippet_links": [{"key": "biological-materials", "type": "definition", "offset": [32, 52]}, {"key": "research-technology", "type": "definition", "offset": [119, 138]}, {"key": "subject-matter", "type": "definition", "offset": [155, 169]}, {"key": "the-activity", "type": "definition", "offset": [218, 230]}, {"key": "nk-cells", "type": "definition", "offset": [243, 251]}, {"key": "for-example", "type": "clause", "offset": [253, 264]}, {"key": "the-production", "type": "clause", "offset": [296, 310]}, {"key": "cell-lines", "type": "definition", "offset": [485, 495]}, {"key": "not-limited", "type": "clause", "offset": [714, 725]}], "samples": [{"hash": "3h2rOZB9sL4", "uri": "/contracts/3h2rOZB9sL4#collaboration-field", "label": "Joint Research, Development, Option and License Agreement (Innate Pharma SA)", "score": 30.7166324435, "published": true}], "snippet": "means any projects, activities, biological materials (including Biological Targets), Know-How (including Materials and Research Technology), IPR and other subject matter the use of which can result inthe modulation of the activity of isolated NK cells (for example resulting in the modulation of the production of cytokine or in the modulation of any biological (including any cell-regulatory) activity of NK cells), as observable in a bioassay comprising only purified NK cells or NK cell lines, with or without any target cells, such modulation being triggered by the binding of any ligand or molecule to any of the cell surface receptors expressed on NK cells or to any of their ligands. These include, but are not limited to: ***", "hash": "0e727a6f35c8e6bcd759079b5615eb2e", "id": 9}, {"size": 1, "snippet_links": [{"key": "field-of", "type": "definition", "offset": [10, 18]}, {"key": "high-throughput-screening", "type": "definition", "offset": [19, 44]}], "samples": [{"hash": "aJkvBjVaGvD", "uri": "/contracts/aJkvBjVaGvD#collaboration-field", "label": "Collaboration Agreement (Aclara Biosciences Inc)", "score": 18.0, "published": true}], "snippet": "means the field of High Throughput Screening.", "hash": "0cacfe4a049cd83ff466b45e7f2d2de4", "id": 10}], "next_curs": "CmASWmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjwLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIcY29sbGFib3JhdGlvbi1maWVsZCMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"size": 35, "title": "Collaboration Field", "snippet": "means the treatment and prevention of eye diseases in humans; provided, however, that the treatment and prevention of [*] is excluded from the Collaboration Field.", "id": "collaboration-field", "examples": ["Alimera is granted a license under this Agreement to market, distribute and/or sell any Product in the <strong>Collaboration Field</strong> in the Territory, including, but not limited to, the right to conduct marketing, reimbursement (e.g., seeking and maintaining pricing and reimbursement approvals from Third Party payors), sales and distribution activities.", "Prior to the Profitability Date for each Product, Alimera shall retain all Gross Sales generated from such Product in the <strong>Collaboration Field</strong> in the Territory.", "Subject to Sections 3.1.1 and 3.1.2 below, (a) CDS and Alimera shall undertake development activities for the Products in the <strong>Collaboration Field</strong> in accordance with this Agreement and (b) during the course of performing such activities, CDS and Alimera shall communicate regularly and shall assume certain rights and responsibilities for the development of the Products in the <strong>Collaboration Field</strong> in accordance with this Agreement.", "Subject to the terms and conditions of this Agreement, CDS hereby grants to Alimera an exclusive (even as to CDS) right and license under CDS\u2019 interest (i.e. subject to the UKRF Licenses) in the CDS Technology, solely to make, have made, use, offer to sell, sell, and import First Product in the <strong>Collaboration Field</strong> in the Territory.", "Subject to the exclusivity obligations of Section 2, payment obligations under Section 4.3, and Illumina&#x27;s reservation of rights under Section 6.3.4, Illumina grants to PEB an exclusive royalty-free license under Illumina&#x27;s interest in Subject Intellectual Property to make, have made, import, use, offer to sell, and sell Instruments and Reagents in the <strong>Collaboration Field</strong>.", "Arrays for Internal ------------------------------------------------------------------- Use Within the <strong>Collaboration Field</strong>.", "Notwithstanding the license -------------------------------- grants of Sections 6.3.1, 6.3.2, and 6.3.3, Illumina retains the right to use Instruments, Reagents, and Assembled Arrays in the <strong>Collaboration Field</strong> for Illumina&#x27;s internal use in furtherance of the Joint Development Program and not for resale, services or other use except as provided for in the Early Access Program set forth in Section 3.6.", "Reata acknowledges and agrees that (x) it solely shall pay all amounts and other consideration payable or issuable to Third Parties pursuant to any Existing Reata License, and no such payment shall constitute a Development Cost or Commercialization Cost hereunder and (y) it shall not grant to any Third Party any sublicense under any Existing Reata License to Exploit any product in the New <strong>Collaboration Field</strong>.", "Except as may be expressly permitted herein, during the ----------- term of this Agreement neither Party nor its Affiliates will design, develop, manufacture, market, sell, distribute or service any Collaboration Product within the <strong>Collaboration Field</strong> except in accordance with the terms and conditions of this Agreement.", "The Joint Steering Committee, ------------------------------------ at equally shared expense between each Party, will be responsible for the selection, registration and maintenance of all trademarks that it employs in connection with Collaboration Product, and both Parties will own and control such trademarks jointly for use in the <strong>Collaboration Field</strong>."], "related": [["collaboration-product", "Collaboration Product", "Collaboration Product"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"], ["collaboration-ip", "Collaboration IP", "Collaboration IP"], ["collaboration-know-how", "Collaboration Know-How", "Collaboration Know-How"], ["licensed-field", "Licensed Field", "Licensed Field"]], "related_snippets": [], "updated": "2025-07-06T21:55:40+00:00"}, "json": true, "cursor": ""}}